1835 ET - Hims & Hers Health says it will stop offering compounded semaglutide, a version of the active ingredient in weight-loss drugs Wegovy and Ozempic, after the first quarter. The stoppage comes after the FDA last week determined that shortages of the drugs had been resolved. CEO Andrew Dudum says on a call with analysts that the company will begin notifying customers of the stop in the coming weeks. "I would suspect, you know, just being very direct, that a lot of those patients will try to go into the open market and try to secure a branded option in some form factor," he says, though he adds that the company will continue to offer other forms of weight-loss drugs on its platform. Shares fall 18% in after-hours trading. (connor.hart@wsj.com)
(END) Dow Jones Newswires
February 24, 2025 18:35 ET (23:35 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。